Therapeutic dendritic cell vaccination of patients with renal cell carcinoma
/in Hypernephroma, International Publications /von 2006-04-18 / Eur. Urol. 2006 Jul;50(1):34-43A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
/in International Publications, Newcastle Disease Virus /von 2006-04-15 / Clin. Cancer Res. 2006 Apr;12(8):2555-62Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
/in International Publications, Prostate Cancer /von 2006-04-13 / Cancer Immunol. Immunother. 2006 Nov;55(11):1432-42Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
/in Dendritic Cells, International Publications, Prostate Cancer /von 2006-04-13 / Cancer Immunol. Immunother. 2006 Dec;55(12):1524-33[Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice]
/in International Publications, Pancreatic Cancer /von 2006-04-11 / Zhonghua Yi Xue Za Zhi 2006 Apr;86(14):943-6Current state and perspectives of dendritic cell vaccination in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2006-04-06 / Skin Pharmacol Physiol 2006;19(3):124-31Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2006-04-06 / Ann. Oncol. 2006 Jun;17(6):974-80Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses
/in Breast Cancer, International Publications /von 2006-04-01 / Clin. Exp. Immunol. 2006 Apr;144(1):41-7Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies
/in Chronic Leukemia, International Publications, Malignant Lymphoma /von 2006-04-01 / Leuk. Lymphoma 2006 Apr;47(4):675-82
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution